Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice

December 6, 2021


Listen to leading experts provide an update on the underlying pathobiology of esophageal squamous cell carcinoma, and review current and emerging therapies.

The experts

  • Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
  • Dr Jean-Phillipe Metges, University Hospital of Brest, Brest, FranceĀ 

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website:

Podbean App

Play this podcast on Podbean App